WASHINGTON—President Trump’s nominee to lead the Health Department, Robert F. Kennedy Jr., is invested in gene-editing technology and owes significant advances on several books, according to financial disclosures released ahead of his confirmation hearings.
The disclosures provide the clearest view to date of RFK Jr.’s investments, employment and potential conflicts of interest. They show he plans to divest stock holdings, including stakes in biotech companies Crispr Therapeutics AG and Dragonfly Therapeutics. He is also getting rid of roles at his law firm and at the anti-vaccine nonprofit Child Health Defense.
Trump tapped RFK Jr. to lead the Department of Health and Human Services after Kennedy ended his presidential campaign and endorsed Trump. Confirmation hearings have not yet been scheduled.
This article is exclusive to STAT+ subscribers
Unlock this article – plus daily biotech sector coverage and analysis – by subscribing to Stat+.
Do you already have an account? Login
View all plans
To read the rest of this story, subscribe to STAT+.
Subscribe